In search of future blockbusters, Big Pharma turns to psychedelics
By Steve Scherer ( August 6, 2026, 21:15 GMT | Comment) -- Eli Lilly's acquisition of AtaiBeckley last month signals that major drugmakers increasingly view psychedelics as a promising source of future psychiatric medicines and new patent-protected drug franchises.Eli Lilly's announcement last month that it will spend as much as $3.8 billion on psychedelic therapeutics developer AtaiBeckley is the clearest sign yet that major pharmaceutical companies have their sights set on the once-fringe field....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.